The United States of America, As Represented by the Secretary, Department of Health and Human Services

Biomed Valley Discoveries, Inc.

Lentigen Technology, Inc.

Memorial Sloan Kettering Cancer Center

Purdue Research Foundation

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

The Scripps Research Institute

The Hong Kong University of Science and Technology

The Children's Hospital of Philadelphia

Other

US Government As Represented by the Secretary of the Army

University of Pittsburgh

The United States of America As Represented by the Department of Health

Fudan University

Veritech Limited

Dimiter Stanchev Dimitrov

Zhongyu Zhu

Rimas J Orentas

Boro Dropulic

Dina Schneider

Saurabh Saha

Yang Feng

Xiaoyan Michelle Zhang

Brad St Croix

Weizao Chen

Enrique Zudaire

Ira H Pastan

Crystal L Mackall

Tianlei Ying

Michel Sadelain

Mitchell Ho

Xiaodong Xiao

Mei-Yun Zhang

Bradley St Croix

Dean Welsch

Mingqian Feng

Philip Stewart Low

Christopher C Broder

Wei Gao

Gary DeCrescenzo

Terry J Fry

Prasad S Adusumilli

Jiayin Shen

Jeffrey Baron

Julian Chun Kin Lui

Crystal Sao Fong Cheung

Dennis R Burton

Sanjay K Phogat

Nancy Yuk-Yu Ip

Javed Khan

Kit Yu Fu

Sivasubramanian Baskar

Wing Yu Fu

John M Maris

Christopher D Chien

Tai Chi Cheuk

Steven Seaman

Yuuei Shu

Dontcho V Jelev

Reuben Benjamin

Qi Zhao

Maxime Moulard

Xiadong Xiao

Kwok Yung Yuen

Joost J Oppenheim

Wei Li

Gary A Decrescenzo

De Yang

Boopathy Ramakrishnan

Pradman K Qasba

John W Mellors

Haiying Qin

Nan Li

Nayanendu Saha

Dorothea Robev

Thomas Edgeworth White

Sneha Ramakrishna

Chuan Chen

Dimitar Nikolov

Kristopher R Bosse

Zehua Sun

Prabakaran Ponraj

Robyn Tovah Sussman

Xin Chen

Tina W Ju

Zhewei Tang

Heungnam Kim

Kei Amemiya

Zhu Zhongyu

Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.

Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use

Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD38 immunotherapy

The present invention provides various ADAM17 binding molecules (including antibodies and fragments thereof), compositions comprising such ADAM17 binding molecules, and methods of using such ADAM17 binding molecules and compositions, for example in inhibiting binding of ADAM17 to ADAM17 substrates (such as ErbB ligands), in inhibiting the proliferation of cancer cells, and in treating cancer.

ADAM17 binding molecules and uses thereof

Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD123 immunotherapy

The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vector are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.

Human monoclonal antibodies against EphA4 and their use

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

Methods of treatments using antigen-binding proteins targeting CD56

Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.

Human monoclonal antibodies specific for FLT3 and uses thereof

Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.

Affinity matured CD22-specific monoclonal antibody and uses thereof

Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD22 immunotherapy

Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.

Anti-CD276 antibodies (B7H3)

The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.

Glypican 2 as a cancer marker and therapeutic target

The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

M971 chimeric antigen receptors

Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD19 immunotherapy

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors

Growing community of inventors

Frederick, MD, United States of America

Dimiter Stanchev Dimitrov